Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | ANPEP | P15144 | 2/20 | 0.46 |
| ▸ | ESR1 | P03372 | 1/20 | 0.45 |
| ▸ | PGR | P06401 | 1/20 | 0.45 |
| ▸ | HTR1A | P08908 | 1/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.45 |
| ▸ | AR | P10275 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | GLP1R | P43220 | 8/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.41 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19499046 | 1.00 | MAPK1 (0.48) | MAPK1ANPEPESR1PGRHTR1A | |
| SCHEMBL19499832 | 1.00 | MAPK1 (0.48) | MAPK1ANPEPESR1PGRHTR1A | |
| SCHEMBL20250952 | 1.00 | MAPK1 (0.48) | MAPK1ANPEPESR1PGRHTR1A | |
| SCHEMBL18568417 | 1.00 | MAPK1 (0.48) | MAPK1ANPEPESR1PGRHTR1A | |
| SCHEMBL21086224 | 1.00 | MAPK1 (0.48) | MAPK1ANPEPESR1PGRHTR1A | |
| SCHEMBL23730428 | 1.00 | MAPK1 (0.48) | MAPK1ANPEPESR1PGRHTR1A | |
| SCHEMBL18490702 | 1.00 | MAPK1 (0.48) | MAPK1ANPEPESR1PGRHTR1A | |
| SCHEMBL18584219 | 1.00 | MAPK1 (0.48) | MAPK1ANPEPESR1PGRHTR1A | |
| SCHEMBL21207336 | 1.00 | MAPK1 (0.48) | MAPK1ANPEPESR1PGRHTR1A | |
| SCHEMBL20250948 | 1.00 | MAPK1 (0.48) | MAPK1ANPEPESR1PGRHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3331892-B1 | PROCESSES FOR THE PREPARATION OF GALNAC ACID DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2019-07-03 | — | — | EP | disclosed |
| EP-3023495-B1 | COMPOSITIONS FOR TARGETED DELIVERY OF SIRNA | ARROWHEAD PHARMACEUTICALS INC (US) | 2019-05-08 | — | — | EP | disclosed |
| US-20170204408-A9 | Compositions for Targeted Delivery of siRNA | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2017-07-20 | — | — | US | disclosed |
| US-20170056472-A1 | Peptide-Based In Vivo siRNA Delivery System | Arrowhead Pharmaceuticals, Inc. | 2017-03-02 | — | — | US | disclosed |
| US-9526796-B2 | Peptide-based in vivo siRNA delivery system | Arrowhead Pharmaceuticals, Inc. (US) | 2016-12-27 | — | — | US | disclosed |
| US-20160222384-A1 | Compositions for Targeted Delivery of siRNA | ARROWHEAD MADISON INC (US) | 2016-08-04 | — | — | US | disclosed |
| EP-3023495-A1 | COMPOSITIONS FOR TARGETED DELIVERY OF SIRNA | Arrowhead Research Corporation (US) | 2016-05-25 | — | — | EP | disclosed |
| US-9345775-B2 | Compositions for targeted delivery of siRNA | Arrowhead Madison Inc. (US) | 2016-05-24 | — | — | US | disclosed |
| US-20150352221-A1 | Peptide-Based In Vivo siRNA Delivery System | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2015-12-10 | — | — | US | disclosed |
| US-9107957-B2 | Peptide-based in vivo siRNA delivery system | Arrowhead Madison Inc. (US) | 2015-08-18 | — | — | US | disclosed |
| US-20150202298-A1 | Compositions for Targeted Delivery of siRNA | Arrowhead Pharmaceuticals, Inc. | 2015-07-23 | — | — | US | disclosed |
| US-9011919-B2 | Compositions for targeted delivery of siRNA | Arrowhead Madison Inc. (US) | 2015-04-21 | — | — | US | disclosed |
| US-20130281658-A1 | Peptide-Based In Vivo siRNA Delivery System | Arrowhead Pharmaceuticals, Inc. | 2013-10-24 | — | — | US | disclosed |
| US-20130245091-A1 | Compositions for Targeted Delivery of siRNA | Arrowhead Madison Inc. (US) | 2013-09-19 | — | — | US | disclosed |
| US-8501930-B2 | Peptide-based in vivo siRNA delivery system | Arrowhead Madison Inc. (US) | 2013-08-06 | — | — | US | disclosed |
| US-8313772-B2 | Compositions for targeted delivery of siRNA | Arrowhead Madison Inc. (US) | 2012-11-20 | — | — | US | disclosed |
| US-20110207799-A1 | Compositions for Targeted Delivery of siRNA | ROCHE MADISON INC. (US) | 2011-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160222384-A1 | Compositions for Targeted Delivery of siRNA | PHAX, RNASE1, SNRPE | MAPK1 4500/4885ANPEP 2112/4885ESR1 4683/4885 |
| US-20170056472-A1 | Peptide-Based In Vivo siRNA Delivery System | VIP, RNASE1, APLNR | MAPK1 3924/4885ANPEP 65/4885ESR1 4680/4885 |
| US-20150202298-A1 | Compositions for Targeted Delivery of siRNA | PHAX, RNASE1, SNRPE | MAPK1 4500/4885ANPEP 2112/4885ESR1 4683/4885 |
| US-20150352221-A1 | Peptide-Based In Vivo siRNA Delivery System | VIP, RNASE1, APLNR | MAPK1 3924/4885ANPEP 65/4885ESR1 4680/4885 |
| US-20110207799-A1 | Compositions for Targeted Delivery of siRNA | PHAX, RNASE1, SNRPE | MAPK1 4500/4885ANPEP 2112/4885ESR1 4683/4885 |
| US-20170204408-A9 | Compositions for Targeted Delivery of siRNA | PHAX, RNASE1, SNRPE | MAPK1 4500/4885ANPEP 2112/4885ESR1 4683/4885 |
| US-20130281658-A1 | Peptide-Based In Vivo siRNA Delivery System | VIP, RNASE1, APLNR | MAPK1 3924/4885ANPEP 65/4885ESR1 4680/4885 |
| US-20130245091-A1 | Compositions for Targeted Delivery of siRNA | PHAX, RNASE1, SNRPE | MAPK1 4500/4885ANPEP 2112/4885ESR1 4683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.